EURTAC phase III trial

Response rates and PFS were significantly higher in erlotinib-treated European patients with EGFR Mut+ NSCLC compared with chemotherapy-treated patients. Erlotinib was also better tolerated.1,2

Study design and endpoints1

  • EURTAC was a randomised phase III trial that took place across 42 hospitals in France, Italy and Spain. 
  • The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.

ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results


Patients who received erlotinib had significantly better response rates than patients receiving chemotherapy.


Patients who received erlotinib had significantly longer PFS than patients receiving chemotherapy.


Erlotinib-treated patients with pre-existing T790M mutations had significantly shorter median PFS than those who were T790M-negative (p=0.0185).


Erlotinib had a more favourable safety profile than chemotherapy in this patient population.

Please click here for further safety data